JD Denham on Retatrutide: Triple Agonist Mechanism, Dosing, and Fat Loss Claims — Fact Check
JD Denham and William T. Hos, co-hosts of the Peptide of the Week podcast, devoted an episode to breaking down retatrutide for new listeners. They cover how the triple agonist mechanism works, who should take it, dosing protocols, stacking with other peptides, and diet recommendations. They call retatrutide "a scientific breakthrough" and "the closest thing we have to a magic pill."
This page fact-checks their key claims against published clinical trial data from the Phase 2 NEJM paper and Eli Lilly's TRIUMPH Phase 3 program.
The Triple Agonist Mechanism
Hos explains that retatrutide works on three receptors — GLP-1 for appetite suppression, GIP for nutrient partitioning and insulin sensitivity, and glucagon (GCG) for boosting metabolic rate and burning fat. He contrasts this with semaglutide (GLP-1 only) and tirzepatide (GLP-1 + GIP).
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide is a triple agonist: GLP-1, GIP, and glucagon | Confirmed. Jastreboff et al. (2023) NEJM: retatrutide is a single peptide with agonism at GLP-1, GIP, and glucagon receptors. It has 0.4x GLP-1 potency, 8.9x GIP potency, and 0.3x glucagon potency relative to endogenous ligands. | Accurate |
| Semaglutide only works on GLP-1 | Correct. Semaglutide is a selective GLP-1 receptor agonist. Tirzepatide targets GLP-1 and GIP (dual agonist). | Accurate |
| GLP-1 makes your stomach digest things slowly — that's the appetite suppression | Gastric emptying delay is a well-established GLP-1 effect. The NEJM Phase 2 paper describes appetite suppression as a primary GLP-1 mechanism. | Accurate |
| GIP acts as a nutrient partitioner — puts protein into muscle | GIP improves insulin sensitivity and affects lipid handling, primarily through brown adipose tissue (EMBO Reports, 2025). However, no published human trial demonstrates GIP specifically "partitioning protein to muscles." This is speculative. | Overstated |
| The glucagon component boosts metabolic rate and tells fat cells to burn off | Glucagon receptor agonism increases hepatic fat oxidation and energy expenditure in preclinical models. However, a cotadutide Phase 2a trial found that in humans, weight loss was "predominantly via reduced energy intake rather than changes in energy expenditure." Directionally correct but magnitude uncertain. | Approximately accurate |
The basic framework is correct — retatrutide genuinely is a triple agonist, and each receptor does play a distinct role. The oversimplification is in attributing muscle-sparing specifically to GIP "nutrient partitioning," which is not supported by published human data.
For a detailed breakdown of how retatrutide works, see What Is Retatrutide (GLP-3)?.
Muscle Loss: Semaglutide vs Retatrutide
Hos claims that people on semaglutide "lost fat and muscle equally" and that retatrutide protects muscle because GIP partitions protein into muscles.
| Claim | Published Data | Verdict |
|---|---|---|
| People on semaglutide lost fat and muscle equally | STEP 1 DXA substudy: semaglutide 2.4 mg produced roughly 60-65% fat mass loss and 35-40% lean mass loss — significantly more fat than lean, nowhere near equal. A systematic review (Bikou et al., 2024) of six studies found lean mass loss ranged from 0% to 40% of total weight loss. | Significantly wrong |
| Retatrutide protects muscle because GIP partitions protein to muscles | Retatrutide Phase 2 DXA data showed approximately 74% fat loss and 26% lean mass loss at 12 mg — broadly comparable to the typical "one-quarter lean mass" ratio seen with other weight loss interventions. No published trial has demonstrated that GIP specifically partitions protein to muscles. | Overstated |
| Tirzepatide also helps with muscle preservation compared to semaglutide | SURMOUNT-1 showed tirzepatide had roughly 80% fat loss / 20% lean mass loss, better than semaglutide. However, attributing this solely to GIP is speculative. | Approximately accurate |
This is one of the most misleading claims in the episode. Semaglutide does not cause "equal" fat and muscle loss — published data consistently shows fat loss accounts for 60-75% of total weight lost. While retatrutide may offer modestly better body composition outcomes, the mechanism Hos describes (GIP protein partitioning) has no published human evidence supporting it.
For the full body composition data, see Retatrutide and Muscle Loss.
The "No Nausea" Claim
Hos claims that retatrutide's higher GIP activity "kills all of the nausea" and that "there is no nausea" on retatrutide, unlike semaglutide or tirzepatide.
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide has no nausea | Phase 2 NEJM data (Jastreboff et al., 2023): nausea rates were 18-25% across dose groups. The 12 mg group had 45% nausea (28 of 62 participants). Vomiting occurred in 19% of the 12 mg group. | Significantly wrong |
| GIP component kills nausea from GLP-1 | A 2025 Science Advances paper from Eli Lilly showed GIP co-treatment "completely prevented emesis caused by semaglutide" in musk shrews. Clinical translation to humans is plausible but nausea rates in retatrutide trials remain substantial. | Approximately accurate (preclinically) |
| Tirzepatide had some nausea but retatrutide eliminates it | SURMOUNT-1: tirzepatide nausea 24-31% across doses. Retatrutide Phase 2: 18-45% across doses. Retatrutide nausea is comparable to or higher than tirzepatide at the highest doses. | Significantly wrong |
This is the most dangerously wrong claim in the episode. Nearly half of participants on the highest retatrutide dose experienced nausea in the Phase 2 trial. GI side effects were described as "transient, mostly mild-to-moderate" and occurred "primarily during dose escalation," but calling them nonexistent is false and could leave new users unprepared.
For the complete side effect profile, see Retatrutide Side Effects.
Brain Function and Mental Clarity
Hos describes experiencing enhanced focus and mental clarity on retatrutide. He attributes this to the glucagon component creating just the right amount of blood sugar through gluconeogenesis, keeping the brain fueled even when fasting.
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide enhances brain function and focus | No published retatrutide trial has measured cognitive endpoints. The Phase 2 and Phase 3 trials did not include neurological or cognitive assessments. | No evidence (anecdotal) |
| The glucagon component creates "just the right amount" of blood sugar for the brain | Glucagon does stimulate hepatic gluconeogenesis. Retatrutide improved glycemic control in Phase 2 (HbA1c reductions of 0.4-0.7% in non-diabetic participants). However, linking this to subjective "brain function" enhancement is speculative. | Overstated |
| GLP-1 receptor agonists have neuroprotective properties | There is a growing body of preclinical research on GLP-1R agonist neuroprotection (reduced neuroinflammation, improved brain insulin signaling). However, direct neuroimaging studies for retatrutide are lacking. | Plausible but unproven for retatrutide |
Hos's personal experience of improved focus is a common anecdotal report among GLP-1 drug users, and there are plausible biological mechanisms. But no clinical trial has measured cognitive outcomes for retatrutide, and attributing this to a specific gluconeogenesis mechanism is speculative.
Retatrutide Dosing Schedule: What They Recommend vs Clinical Trials
Denham shares his personal experience of injecting 1 mg three times per week (Monday, Wednesday, Friday) for a total of 3 mg/week. Hos states the "clinical starting dose is 2 and a half milligrams a week" and recommends titrating up by 0.5 mg per injection.
| Claim | Published Data | Verdict |
|---|---|---|
| Clinical starting dose is 2.5 mg/week | Phase 2 (NEJM): starting dose was 2 mg once weekly for 4 weeks. Phase 3 (TRIUMPH-4): same 2 mg starting dose. There is no 2.5 mg dose in the clinical program. The 2.5 mg figure may be confused with tirzepatide (Mounjaro starts at 2.5 mg). | Misleading |
| Dosing should be split into three injections per week (e.g., 1 mg MWF) | All clinical trials administered retatrutide as a single once-weekly subcutaneous injection. Three-times-weekly dosing has never been studied in any published trial. The half-life supports once-weekly dosing. | Not based on clinical data |
| Weight loss sweet spot is 5-6 mg/week for people who need to lose a lot | Phase 2 tested 1, 4, 8, and 12 mg once weekly. Phase 3 (TRIUMPH-4) tested 8 and 12 mg. The 12 mg group achieved 28.7% weight loss at 68 weeks. There is no published efficacy data for 5-6 mg/week. | Not based on clinical data |
| Titration schedule: increase by 0.5 mg per injection every 2-3 weeks | Clinical titration: 2 mg (weeks 1-4) → 4 mg (weeks 5-8) → 8 mg (weeks 9-12) → 12 mg (week 13+). This is a doubling schedule with 4-week intervals, not 0.5 mg increments. | Not based on clinical data |
The dosing discussion is the most problematic section of the episode. Every dosing recommendation they make — the frequency, the starting dose, the titration schedule, and the target dose — diverges from published clinical trial protocols. Their advice appears to come from gray market peptide community practices rather than the studied regimens that produced the published weight loss and safety data.
For the clinical dosing schedule, see Retatrutide Dosage Guide.
Visceral Fat and Metabolic Benefits
Both hosts emphasize that retatrutide is particularly effective at burning visceral (belly) fat, and that this is driven by the glucagon receptor component.
| Claim | Published Data | Verdict |
|---|---|---|
| Retatrutide burns visceral fat exceptionally well | Phase 2 data: visceral fat decreased by 42% at 48 weeks (12 mg group), exceeding the 24.2% total body weight loss. Liver fat decreased by approximately 50%. | Approximately accurate |
| The glucagon component specifically targets visceral fat | Glucagon receptor agonism has established mechanisms for hepatic fat oxidation. However, visceral fat is naturally the first fat depot mobilized during weight loss, so some of this effect may simply reflect the magnitude of weight loss rather than targeted visceral action. | Approximately accurate |
| If you are already lean, it will just burn belly fat in a week and a half | Phase 2 trial used a 48-week endpoint. Meaningful body composition changes were measured over months, not days. The claim of visible results in 10 days at a low dose is anecdotal and not supported by trial timelines. | Overstated |
The visceral fat reduction data is real and impressive — a 42% reduction is substantial. But claiming visible results "in a week and a half" at low doses goes well beyond what the clinical trials measured.
For more on retatrutide and fat loss, see Retatrutide Results.
Peptide Stacking Recommendations
The hosts recommend stacking retatrutide with tesamorelin, L-carnitine, 5-amino-1MQ, and MOTS-c for fat burning, and with MK-677 and IGF-1 LR3 for muscle building.
| Claim | Published Data | Verdict |
|---|---|---|
| Tesamorelin targets belly fat and boosts growth hormone | Tesamorelin is FDA-approved for HIV-associated lipodystrophy and reduces visceral fat by stimulating growth hormone. However, it has never been studied in combination with retatrutide. | Partially accurate (but no combination data) |
| L-carnitine tells your body to burn fat over sugar | L-carnitine facilitates fatty acid transport into mitochondria. Systematic reviews show modest fat loss benefits in overweight populations. It does not fundamentally "switch" the body from burning sugar to burning fat. | Overstated |
| MK-677 will offset reta's appetite suppression and help you eat more | MK-677 (ibutamoren) stimulates ghrelin receptors and increases appetite. It is not FDA-approved for any indication and has potential risks including insulin resistance and increased cortisol. | Partially accurate (but safety concerns omitted) |
None of these stacking protocols have been studied in combination with retatrutide. The hosts are describing gray market peptide community practices, not evidence-based protocols. Several of these compounds (MK-677, IGF-1 LR3, 5-amino-1MQ) are research chemicals without FDA approval for any human use.
Frequently Asked Questions
Who are JD Denham and William Hos from Peptide of the Week?
JD Denham and William T. Hos are the co-hosts of the Peptide of the Week podcast, a YouTube show focused on peptides, supplements, and fitness. They also run Warrior Maker, a brand that sells peptide-related products. They are not physicians or scientists. Their discussion mixes personal anecdotes with general science, and their dosing recommendations come from gray market community practices rather than clinical trials.
Is retatrutide really a triple agonist?
Yes. Retatrutide is genuinely a triple agonist targeting the GLP-1, GIP, and glucagon receptors. This has been confirmed in the Phase 2 NEJM paper (Jastreboff et al., 2023) and structural studies published in Nature Cell Discovery (Li et al., 2024). It is the first triple agonist to reach Phase 3 clinical trials. For a full explanation, see What Is Retatrutide?.
Does retatrutide really have no nausea?
No. Retatrutide causes significant nausea in clinical trials. The Phase 2 trial reported nausea rates of 18-45% depending on dose, with the highest dose (12 mg) causing nausea in 45% of participants. GI side effects were described as transient and mostly mild-to-moderate, occurring primarily during dose escalation. For the full safety profile, see Retatrutide Side Effects.
What is the correct retatrutide dosing schedule?
In clinical trials, retatrutide is administered as a single once-weekly subcutaneous injection. The titration schedule is: 2 mg once weekly for weeks 1-4, then 4 mg for weeks 5-8, then 8 mg for weeks 9-12, then 12 mg from week 13 onward. The three-times-weekly dosing discussed in this podcast has never been studied in published trials. For the complete dosing guide, see Retatrutide Dosage.
Does semaglutide cause equal fat and muscle loss?
No. Published DXA data from the STEP 1 trial shows semaglutide produces roughly 60-65% fat mass loss and 35-40% lean mass loss — significantly more fat than lean. A systematic review of six studies (Bikou et al., 2024) found lean mass loss ranged from 0% to 40% of total weight loss with semaglutide, with the proportion of lean mass relative to total body mass actually increasing. For retatrutide body composition data, see Retatrutide and Muscle Loss.
Does retatrutide burn visceral fat better than other weight loss drugs?
Phase 2 data shows retatrutide reduced visceral fat by 42% at 48 weeks on the 12 mg dose, which exceeded the 24.2% total body weight loss. Liver fat decreased by approximately 50%. The glucagon receptor component likely contributes to hepatic fat oxidation, though visceral fat is also naturally the first depot mobilized during any significant weight loss. For the full results, see Retatrutide Results.
Sources
- Denham, JD & Hos, W. (2025). "Peptide of the Week: Retatrutide (GLP-3) – Fat Loss, Brain Boost & Total Control." Peptide of the Week Podcast. Watch on YouTube
- Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
- Eli Lilly and Company. (2025). Lilly's triple agonist retatrutide delivered weight loss of up to an average 28.7% in adults with obesity at 68 weeks. Press release
- Bikou, A., et al. (2024). Changes in body composition under semaglutide treatment in adults: A systematic review. Expert Opinion on Pharmacotherapy.
- Samms, R.J., et al. (2025). GIP receptor agonism attenuates GLP-1 receptor agonist–induced nausea and emesis. Science Advances. DOI: 10.1126/sciadv.adu1589
- Li, X., et al. (2024). Structural basis of retatrutide action at GLP-1, GIP, and glucagon receptors. Nature Cell Discovery. DOI: 10.1038/s41421-024-00700-0
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.
The Peptide of the Week podcast is not medical advice. JD Denham and William Hos are not physicians or scientists. Their dosing recommendations diverge significantly from published clinical trial protocols and appear to be based on gray market community practices. Several of the compounds they discuss (MK-677, IGF-1 LR3, 5-amino-1MQ) are not FDA-approved for any human use.
Do not use this information to make decisions about your health without consulting a qualified healthcare provider.
This site is not affiliated with JD Denham, Peptide of the Week, Warrior Maker, Eli Lilly and Company, or any pharmaceutical manufacturer.
Sources
- Peptide of the Week: Retatrutide (YouTube)
YouTube
- Phase 2 trial (NEJM)
New England Journal of Medicine
- GIP attenuates GLP-1 nausea
Science Advances
Related reading
What Is Retatrutide (GLP-3)?
The world's first triple agonist weight loss drug — how it works, what the trials show, and why people call it GLP-3.
Retatrutide Dosage & Dosing Guide
How retatrutide is dosed in clinical trials — titration schedule, dose levels, and what each dose achieved.
Retatrutide Side Effects & Safety
Clinical trial safety data, the new dysesthesia signal, and how side effects compare to existing GLP-1 drugs.
Does Retatrutide Cause Muscle Loss?
The first DXA body composition data for retatrutide, the glucagon muscle-sparing hypothesis, and evidence-based strategies to preserve lean mass.
Retatrutide Results: Weight Loss Data and What to Expect
28.7% average weight loss in Phase 3 — here's the full data breakdown by dose, timeline, and what individual results look like.